NASDAQ · Financial Statements

SOPHiA GENETICS SA (SOPH) Revenue, Earnings & Financial Statements

$7.45 NASDAQ: SOPH Market Cap $634.20M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

SOPHiA GENETICS SA most recently reported annual revenue of $77.0M, a net loss of $79.0M. Revenue grew at an average annual rate of 22.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

SOPHiA GENETICS SA: Revenue rose from $25.0M in 2019 to $77.0M in 2025, a change of +208.0% over 6 years; net profit was positive in 0 of 7 reported years; operating margin moved from -127.3% to -91.8%, a shift of +35.5 percentage points; the most recent year shows a net loss of $79.0M.

Income Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Revenue—$25.0M$28.0M$40.0M$48.0M$62.0M$65.0M$77.0M
Operating Expenses—$58.0M$66.0M$112.0M$135.0M$137.0M$132.0M$148.0M
Operating Profit—−$32.0M−$37.0M−$71.0M−$88.0M−$75.0M−$67.0M−$71.0M
Operating Margin—-127.3%-131.6%-176.7%-184.7%-120.0%-102.1%-91.8%
Other Income—−$1.0M−$4.0M−$2.0M$0−$4.0M$5.0M−$8.0M
Interest$0$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M$5.0M
Depreciation—$2.0M$2.0M$4.0M$6.0M$8.0M$9.0M$10.0M
Profit Before Tax—−$34.0M−$41.0M−$74.0M−$88.0M−$78.0M−$61.0M−$78.0M
Tax rate (%)—-0.5%4.6%-0.2%0.2%-0.6%-2.0%-0.7%
Net Profit—−$34.0M−$39.0M−$74.0M−$87.0M−$79.0M−$62.0M−$79.0M
EPS$—−$0.53−$0.82−$1.33−$1.36−$1.22−$0.95−$1.17

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$17.0M$16.0M$16.0M$16.0M$18.0M$18.0M$18.0M$19.0M$22.0M$22.0M$23.0M$24.0M
Operating Expenses$36.0M$35.0M$31.0M$31.0M$35.0M$34.0M$37.0M$37.0M$40.0M$39.0M$43.0M$42.0M
Operating Profit−$19.0M−$19.0M−$15.0M−$15.0M−$17.0M−$16.0M−$19.0M−$18.0M−$18.0M−$17.0M−$20.0M−$18.0M
Operating Margin-111.1%-118.9%-94.9%-96.9%-98.4%-90.2%-101.3%-91.8%-83.2%-79.7%-86.0%-73.5%
Interest$0$0$1.0M$0$0$1.0M$1.0M$2.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax−$24.0M−$13.0M−$15.0M−$18.0M−$15.0M−$17.0M−$22.0M−$19.0M−$20.0M−$19.0M−$22.0M−$20.0M
Tax rate (%)-0.0%-2.4%-1.1%-0.7%-4.2%-3.0%-3.5%-3.3%2.0%-1.3%-0.3%-1.6%
Net Profit−$24.0M−$14.0M−$15.0M−$18.0M−$15.0M−$17.0M−$22.0M−$20.0M−$19.0M−$19.0M−$22.0M−$20.0M
EPS−$0.37−$0.21−$0.23−$0.28−$0.23−$0.26−$0.33−$0.30−$0.28−$0.27−$0.30−$0.24

Over the 8 years reported for SOPHiA GENETICS SA, borrowings increased from $9.0M in 2018 to $63.0M in 2025, cash stood at $70.0M in the latest year, shareholders' equity was $5.0M, current assets covered current liabilities 1.94 times.

Balance Sheet — 8 Years (USD millions)

Metric20182019202020212022202320242025
Total Assets$77.0M$52.0M$132.0M$320.0M$244.0M$206.0M$155.0M$163.0M
Current Assets$63.0M$34.0M$110.0M$283.0M$196.0M$148.0M$99.0M$99.0M
Cash$54.0M$18.0M$75.0M$193.0M$161.0M$123.0M$80.0M$70.0M
Inventory$3.0M$4.0M$3.0M$6.0M$5.0M$6.0M$6.0M$6.0M
Receivables$5.0M$10.0M$8.0M$7.0M$8.0M$15.0M$9.0M$19.0M
Fixed Assets$5.0M$6.0M$6.0M$16.0M$21.0M$23.0M$19.0M$18.0M
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments$1.0M$1.0M$23.0M$72.0M$17.0M$0$0$2.0M
Other Assets$8.0M$8.0M$9.0M$8.0M$8.0M$9.0M$8.0M$10.0M
Total Liabilities$22.0M$29.0M$32.0M$45.0M$44.0M$55.0M$59.0M$116.0M
Current Liabilities$11.0M$19.0M$22.0M$29.0M$27.0M$36.0M$27.0M$51.0M
Borrowings$9.0M$8.0M$7.0M$13.0M$17.0M$19.0M$30.0M$63.0M
Other Liabilities$13.0M$21.0M$24.0M$32.0M$27.0M$36.0M$29.0M$53.0M
Equity$2.0M$2.0M$2.0M$3.0M$3.0M$4.0M$4.0M$5.0M
Reserves$55.0M$22.0M$101.0M$275.0M$200.0M$151.0M$96.0M$47.0M

For SOPHiA GENETICS SA, operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $39.0M; free cash flow was positive in 0 of 8 years.

Cash Flow Statement — 8 Years (USD millions)

Metric20182019202020212022202320242025
Operating Cash Flow—−$32.0M−$32.0M−$58.0M−$70.0M−$49.0M−$43.0M−$38.0M
Investing Cash Flow—−$6.0M−$28.0M−$64.0M$32.0M−$1.0M−$16.0M−$11.0M
Financing Cash Flow—$2.0M$1.0M$11.0M$1.0M$0$0$0
Net Cash Flow—−$36.0M$57.0M$118.0M−$32.0M−$38.0M−$43.0M−$10.0M
Free Cash Flow$0−$35.0M−$35.0M−$65.0M−$80.0M−$58.0M−$51.0M−$39.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-2.82
EV / EBITDA-8.17
FCF Yield-8.46%
Quick Ratio2.16
Interest Coverage-11.13
Return 1Y83.95%
Return 3Y102.45%
Return 5Y-52.15%

SOPHiA GENETICS SA (SOPH) financials — frequently asked questions

What is SOPHiA GENETICS SA's annual revenue?

SOPHiA GENETICS SA (SOPH) reported annual revenue of $77.0M in its most recent fiscal year.

What is SOPHiA GENETICS SA's net profit?

SOPHiA GENETICS SA (SOPH) reported a net loss of $79.0M in its most recent fiscal year.

What is SOPH EV/EBITDA?

SOPHiA GENETICS SA's enterprise value to EBITDA (EV/EBITDA) ratio is -8.17. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Healthcare Information Services stocks

VEEV revenue $3.2BGEHC revenue $20.6BBTSG revenue $12.9BTEM revenue $1.3BHNGE stockHQY revenue $1.3BDOCS revenue $645.0MHTFL stockPRVA revenue $2.1BCERT revenue $419.0MAll Medical - Healthcare Information Services stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
SOPH Overview SOPH Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.